USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Research analysts at Sidoti Csr lifted their FY2025 earnings per share (EPS) estimates for USANA Health Sciences in a note issued to investors on Wednesday, July 23rd. Sidoti Csr analyst A. Lebiedzinski now expects that the company will post earnings per share of $2.62 for the year, up from their prior forecast of $2.61. The consensus estimate for USANA Health Sciences' current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences' Q1 2026 earnings at $0.80 EPS, Q2 2026 earnings at $0.77 EPS, Q3 2026 earnings at $0.85 EPS, Q4 2026 earnings at $0.98 EPS and FY2026 earnings at $3.40 EPS.
USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The company reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.20. The company had revenue of $235.85 million for the quarter, compared to analysts' expectations of $225.20 million. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%.
Separately, Wall Street Zen raised USANA Health Sciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd.
Check Out Our Latest Research Report on USANA Health Sciences
USANA Health Sciences Stock Down 0.4%
USNA stock traded down $0.13 during midday trading on Thursday, hitting $31.97. The company's stock had a trading volume of 175,530 shares, compared to its average volume of 137,350. The stock's 50-day moving average price is $30.89 and its 200 day moving average price is $30.05. USANA Health Sciences has a 1 year low of $23.10 and a 1 year high of $45.86. The stock has a market cap of $595.19 million, a price-to-earnings ratio of 17.76, a PEG ratio of 1.02 and a beta of 0.64.
Insider Activity
In related news, CFO G Doug Iiekking sold 4,548 shares of the firm's stock in a transaction that occurred on Friday, May 9th. The stock was sold at an average price of $29.61, for a total transaction of $134,666.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Walter Noot sold 6,291 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $30.29, for a total value of $190,554.39. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,013 shares of company stock valued at $360,149. 0.63% of the stock is owned by company insiders.
Hedge Funds Weigh In On USANA Health Sciences
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Pzena Investment Management LLC raised its stake in shares of USANA Health Sciences by 9.4% in the second quarter. Pzena Investment Management LLC now owns 1,198,260 shares of the company's stock worth $36,583,000 after purchasing an additional 103,074 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in USANA Health Sciences by 46.2% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 188,511 shares of the company's stock valued at $5,084,000 after purchasing an additional 59,535 shares during the period. Dimensional Fund Advisors LP raised its stake in USANA Health Sciences by 7.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company's stock valued at $27,751,000 after purchasing an additional 55,059 shares during the period. Nuveen LLC bought a new stake in USANA Health Sciences during the 1st quarter valued at approximately $895,000. Finally, Charles Schwab Investment Management Inc. raised its stake in USANA Health Sciences by 23.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 173,997 shares of the company's stock valued at $4,693,000 after purchasing an additional 33,141 shares during the period. 54.25% of the stock is currently owned by institutional investors.
USANA Health Sciences Company Profile
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Featured Articles
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access